Resistance of Human Cytomegalovirus to the Benzimidazole L-Ribonucleoside Maribavir Maps to UL27

Journal of Virology

Volumn 77, Issue 21, 2003, Pages 11499-11506

  Komazin, Gloria ^a   Ptak, Roger G ^a,b   Emmer, Brian T ^a   Townsend, Leroy B ^a   Drach, John C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (BETA DEXTRO RIBOFURANOSYL) 2 BROMO 5,6 DICHLOROBENZIMIDAZOLE; 1 (BETA DEXTRO RIBOFURANOSYL) 2,5,6 TRICHLOROBENZIMIDAZOLE; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; GANCICLOVIR; LEUCINE; PHOSPHOTRANSFERASE; PROLINE; RIBONUCLEOSIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; COSMID; DNA PACKAGING; DNA SYNTHESIS; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TARGETING; GENE MAPPING; HUMAN CYTOMEGALOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; UL27 GENE; UL56 GENE; UL89 GENE; UL97 GENE; VIRUS GENE; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELLS, CULTURED; CHROMOSOME MAPPING; CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PLAQUE ASSAY; RIBONUCLEOSIDES; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 0142124151     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.21.11499-11506.2003     Document Type: Article

References (42)

1. Abenes, G., M. Lee, E. Haghjoo, T. Tong, X. Zhan, and F. Liu. 2001. Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. J. Virol. 75:1697-1707.
2. Amin, H. I., E. Ai, H. R. McDonald, and R. N. Johnson. 2000. Retinal toxic effects associated with intravitreal fomivirsen. Arch. Ophthalmol. 118:426-427.
3. Baek, M. C., P. M. Krosky, and D. M. Coen. 2002. Relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. J. Virol. 76:11943-11952.
4. Baek, M. C., P. M. Krosky, Z. He, and D. M. Coen. 2002. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J. Biol. Chem. 277:29593-29599.
5. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
6. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
7. Britt, W. J., R. F. Pass, S. Stagno, and C. A. Alford. 1991. Pediatric cytomegalovirus infection. Transplant Proc. 23:115-117.
8. Chambers, J., A. Angulo, D. Amaratunga, H. Guo, Y. Jiang, J. S. Wan, A. Bittner, K. Frueh, M. R. Jackson, P. A. Peterson, M. G. Erlander, and P. Ghazal. 1999. DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J. Virol. 73:5757-5766.
9. Chrisp, P., and S. P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties, and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
10. Crumpacker, C. S. 1996. Ganciclovir. Drug Ther. 335:721-729.
11. Curran, M., and S. Noble. 2001. Valganciclovir. Drugs 61:1145-1152.
12. Deray, G., F. Martinez, C. Katlama, B. Levaltier, H. Beaufils, M. Danis, M. Rozenheim, A. Baumelou, E. Dohin, M. Gentilini, and C. Jacobs. 1989. Foscarnet nephrotoxicity-mechanism, incidence and prevention. Am. J. Nephrol. 9:316-321.
13. Drocourt, D., T. Calmels, J. P. Reynes, M. Baron, and G. Tiraby. 1990. Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucleic Acids Res. 18:4009.
14. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
15. Field, A. K., and K. K. Biron. 1994. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1-13.
16. Good, S. S., B. S. Owens, L. B. Townsend, and J. C. Drach. 1994. The disposition in rats and monkeys of 2-bromo-5,6-dichloro-1-(β -D-ribofuranosyl)benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antivir. Res. 23:103.
17. Grattan, M. T., C. E. Moreno-Cabral, V. A. Starnes, E. B. Stinson, and N. E. Shumway. 1989. Cytomegalovirus infection is associated with cardiac allograph rejection and atherosclerosis. JAMA 261:3561-3566.
18. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antimicrob. Agents Chemother. 7:115-127.
19. Hobom, U., W. Brune, M. Messerle, G. Hahn, and U. H. Koszinowski. 2000. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J. Virol. 74:7720-7729.
20. Klein, R. J. 1975. Isolation of herpes simplex virus clones and drug resistant mutants in microculture. Arch. Virol. 49:73-80.
21. Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. D. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron. 2002. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46:2373-2380.
22. Koszalka, G. W., S. D. Chamberlain, R. J. Harvey, L. W. Frick, S. S. Good, M. L. Davis, A. Smith, K. K. Biron, J. C. Drach, and L. B. Townsend. 1996. Benzimidazoles For The Treatment Of Hum. Cytomegalovirus. Antivir. Res. 30:A43.
23. Krosky, P. M., M. C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
24. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole nucleoside analogs maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
25. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
26. Lee, E. C., D. Yu, J. Martinez de Velasco, L. Tessarollo, D. A. Swing, D. L. Court, N. A. Jenkins, and N. G. Copeland. 2001. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73:56-65.
27. McKenzie, R., M. W. D. Travis, S. A. Dolan, S. Pittaluga, I. M. Feuerstein, J. Shelhamer, R. Yarchoan, and H. Masur. 1991. The cause of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary disease. Medicine 70:326-343.
28. Patterson, C. E., and T. Shenk. 1999. Human cytomegalovirus UL36 protein is dispensable for viral replication in cultured cells. J. Virol. 73:7126-7131.
29. Perry, C. M., and J. A. Balfour. 1999. Fomivirsen. Drugs 57:375-381.
30. Prichard, M. N., S. R. Turk, L. A. Coleman, S. L. Englehardt, C. J. Shipman, and J. C. Drach. 1990. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 28:101-106.
31. Shipman, C. J. 1969. Evaluation of 4-(2-hydroxyethyl)-1-piperazineë thane-sulfonic acid (HEPES) as a tissue culture buffer. Proc. Soc. Exp. Biol. 130:305-310.
32. Sia, I. G., and R. Patel. 2000. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13:83-121.
33. Sullivan, V., K. K. Biron, C. Talarico, S. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
34. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 38:4098-4105.
35. Townsend, L. B., K. S. Gudmundsson, S. M. Daluge, J. J. Chen, Z. Zhu, G. W. Koszalka, L. Boyd, S. D. Chamberlain, G. A. Freeman, K. K. Biron, and J. C. Drach. 1999. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucleosides Nucleotides 18:509-519.
36. Turk, S. R., C. Shipman, Jr., R. Nassiri, G. Genzlinger, S. H. Krawczyk, L. B. Townsend, and J. C. Drach. 1987. Pyrrolo[2,3-D]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 31:544-550.
37. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
38. Williams, S. L., C. B. Hartline, N. L. Kushner, E. A. Harden, D. J. Bidanset, J. C. Drach, L. B. Townsend, M. R. Underwood, K. K. Biron, and E. R. Kern. 2003. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.
39. Wingard, J. R., S. Piantadosi, W. H. Burns, M. L. Zahurak, G. W. Santos, and R. Saral. 1990. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev. Infect. Dis. 12(Suppl. 7):S793-S804.
40. Wolf, D. G., C. T. Courcelle, M. N. Prichard, and E. S. Mocarski. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. USA 98:1895-1900.
41. Yu, D., H. M. Ellis, E. C. Lee, N. A. Jenkins, N. G. Copeland, and D. L. Court. 2000. An efficient recombination system for chromosome engineering in Escherichia coli. Proc. Natl. Acad. Sci. USA 97:5978-5983.
42. Zacny, V. L., E. Gershburg, M. G. Davis, K. K. Biron, and J. S. Pagano. 1999. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J. Virol. 73:7271-7277.